首頁 > 市場調查報告書 > 醫療設備

導管

市場調查報告書

商品編碼

1297816

全球藥物洗脫支架市場 - 2023-2030年

Global Drug Eluting Stents Market - 2023-2030

出版日期: 2023年06月15日 | 出版商:

DataM Intelligence | 英文 195 Pages | 商品交期: 約2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

市場概況

全球藥物洗脫支架市場在2022年達到63億美元，預計到2030年將見證有利可圖的成長，達到102億美元。在預測期內（2023-2030年），全球藥物洗脫支架市場預計將呈現6.4%的複合成長率。

近年來，隨著心血管疾病發病率的增加和支架技術的進步，全球藥物洗脫支架（DES）市場已大幅成長。全球藥物洗脫支架市場的一些最新趨勢包括對基於生物分解聚合物的DES的日益青睞，適應症的擴大，以及為個別病人客製化支架。

全球藥物洗脫支架（DES）市場正受到多種因素的推動，如心血管疾病發病率的增加，採用創傷性小的手術，以及人口老齡化。例如，根據美國疾病控制和預防中心（CDC）2023年的報告，2021年美國約有69.5萬人死於心臟病，每五個人中就有一個死於心臟病。

市場動態

不斷成長的老齡人口正在推動全球藥物洗脫支架市場的成長

人口老齡化是全球藥物洗脫支架行業的一個主要驅動力。例如，隨著年齡的成長，個人患心血管疾病，特別是冠狀動脈疾病的風險大大增加。介入心臟病學技術經常被用來治療老年人的心血管問題。

例如，根據世界衛生組織（WHO）2022年的報告，到2030年，地球上每六個人中就有一個人是60歲或以上。在這個時間跨度內，60歲及以上的世界人口比例預計將從2020年的10億增加到14億。在2050年，60歲及以上人口的數量將增加兩倍以上，接近21億。

微創手術的採用正在推動全球藥物洗脫支架市場的成長

採用小切口進入身體的微創技術，已經徹底改變了介入心臟病學領域，並重新定義了心血管疾病的治療格局。藥物洗脫支架，塗有藥物以防止動脈再狹窄，為冠狀動脈疾病提供了一個非常成功的微創治療選擇。

較小的切口和對病人解剖結構的破壞較少，使術後疼痛和插入DES的困難減少。此外，醫療技術的進步正在推動微創手術的採用，如DES的插入。基於導管的輸送設備、成像模式和機器人輔助干涉都極大地提高了DES手術的精確度和安全性。這些改進使醫療機構能夠更準確地進行複雜的治療，並改善病人的治療效果。

與藥物洗脫支架相關的高成本阻礙了市場的成長

藥物洗脫支架的價格不斷攀升，是藥物洗脫支架市場進展的一個關鍵障礙。與普通支架相比，這些支架的成本增加是市場成長的一個重要障礙。要求擴大使用藥物洗脫支架的法規的建立，將導致整體支架成本的大幅增加。

例如，根據國家藥品定價局（NPPA）2023年3月發布的命令，由金屬DES和生物可吸收血管支架或生物可分解支架組成的藥物洗脫支架（DES）的上限價格已被修訂為38,265盧比。這兩種類型的支架在2022年4月的最高價格分別為9373盧比和34128盧比。

COVID-19影響分析

全球藥物洗脫支架（DES）市場受到了COVID-19大流行病的巨大影響。由於醫院專注於治療COVID-19患者，包括DES植入在內的選擇性治療的數量減少。此外，由於旅行限制和社會疏遠的努力，這一流行病減少了病人獲得醫療保健的機會。這使得患者更難接受必要的治療，如DES植入。

COVID-19的流行也提高了DES植入的成本。這是由於多種原因造成的，包括更大的PPE成本和由於感染風險增加而必須進行更複雜的手術。植入DES的費用上升，使得一些人越來越難以獲得這種治療。

儘管有COVID-19大流行的障礙，全球DES市場在未來幾年可能會上升。這是因為心血管疾病，如冠狀動脈疾病和周圍動脈疾病正變得越來越普遍。這些疾病是導致世界各地死亡和殘疾的首要原因。

俄羅斯-烏克蘭衝突分析

俄烏衝突對藥物洗脫支架（DES）的全球市場產生了負面影響。戰爭造成了全球供應鏈的中斷，導致DES價格上漲。此外，戰爭還造成了經濟不穩定，從而減少了對DES的需求。因此，全球DES市場的擴張速度可能比戰前要慢。

戰爭造成了全球供應鏈的中斷，導致DES價格上漲。這是由於DES是由一系列組件構成的，其中一些來自俄羅斯或烏克蘭。例如，鈀金是生產DES的一個關鍵部件，而俄羅斯是鈀金的一個大生產國。由於這場戰鬥，鈀的價格上升，導致DES的價格上升。

由於戰爭的經濟不穩定，對DES的需求也下降了。這是因為當經濟不穩定時，人們不太願意花錢做冠狀動脈支架等選擇性手術。因此，全球藥物洗脫支架市場預計將以比戰爭前更慢的速度擴張。市場仍有可能發展，但速度要比沒有戰爭的時候慢一些。

Market Overview

The Global Drug Eluting Stents Market reached US$ 6.3 billion in 2022 and is projected to witness lucrative growth by reaching up to US$ 10.2 billion by 2030. The global drug eluting stents market is expected to exhibit a CAGR of 6.4% during the forecast period (2023-2030).

The global drug-eluting stents (DES) market has grown significantly in recent years as the prevalence of cardiovascular illnesses has increased and stent technologies have advanced. Some of the most recent trends in the globally drug-eluting stents market include the growing preference for biodegradable polymer-based DES, the expansion of indications, and customized stents for individual patients.

The global drug-eluting stents (DES) market is being pushed by multiple factors such as the increasing prevalence of cardiovascular diseases, the adoption of procedures that are less invasive, and an aging population. For instance, according to a 2023 report by the Centers for Disease Control and Prevention (CDC), heart disease accounted for approximately 695,000 deaths in the United States in 2021, accounting for one in every five deaths.

Market Dynamics

The Growing Aging Population is Propelling the Growth of the Global Drug Eluting Stents Market

The aging population is a major driver of the global drug-eluting stents industry. For example, individuals' risk of getting cardiovascular disorders, particularly coronary artery disease, increases considerably as they age. Interventional cardiology techniques are frequently used to treat cardiovascular problems in the elderly.

For instance, according to World Health Organization (WHO) 2022 report, by 2030, about one out of every six people on the planet will be 60 or older. Within this time span, the share of the world population aged 60 and up is expected to increase from 1 billion in 2020 to 1.4 billion. In 2050, the number of persons aged 60 and up will more than treble, approaching 2.1 billion.

The Adoption of Minimally Invasive Procedures is Driving the Growth of the Global Drug Eluting Stents Market

Minimally invasive techniques, that employ small incisions to get access to the body, have revolutionized the area of interventional cardiology and are redefining the therapeutic landscape for cardiovascular diseases. Drug eluting stents, which are coated with medication to prevent the re-narrowing of arteries, provide a highly successful and minimally invasive therapy option for coronary artery disease.

Smaller incisions and less disruption to the patient's anatomy result in less post-operative pain and difficulties with DES insertion. Furthermore, advances in medical technology are driving the adoption of minimally invasive procedures such as DES insertion. Catheter-based delivery devices, imaging modalities, and robotic-assisted interventions have all increased the precision and safety of DES procedures dramatically. These improvements allow healthcare providers to undertake complex therapies with better accuracy and improve patient outcomes.

The High Cost Associated with Drug Eluting Stent is Hampering the Growth of the Market

The escalating price of drug-eluting stents is a key impediment to the drug-eluting stent market's progress. The increased cost of these stents in comparison to regular stents is a significant impediment to market growth. The establishment of regulations requiring the increasing use of drug-eluting stents would result in a large increase in overall stent costs.

For instance, according to an order issued by the National Pharmaceutical Pricing Authority (NPPA) in March 2023, the ceiling price of drug-eluting stents (DES), comprising metallic DES and bio-absorbable vascular scaffold or bio-degradable stents, has been revised to Rs 38,265. The ceiling prices for these two types of stents in April 2022 were Rs 9,373 and Rs 34,128 respectively.

COVID-19 Impact Analysis

The global drug-eluting stent (DES) market has been significantly impacted by the COVID-19 pandemic. As hospitals focused on treating COVID-19 patients, the number of elective treatments, including DES implantations, decreased. Furthermore, because to travel restrictions and social distancing efforts, the epidemic has reduced patient access to healthcare. This has made it more difficult for patients to receive necessary therapy, such as DES implantations.

The COVID-19 epidemic has also raised the cost of DES implantations. This is due to a variety of causes, including greater PPE costs and the necessity for more complex procedures due to the increased risk of infection. The rising expense of DES implantations has made this treatment increasingly difficult to get for some people.

Despite the COVID-19 pandemic's hurdles, the global DES market is likely to rise in the future years. This is because cardiovascular disorders such as coronary artery disease and peripheral artery disease are becoming more common. These diseases are the top causes of mortality and disability around the world.

Russia-Ukraine Conflict Analysis

The Russia-Ukraine conflict is having a negative influence on the global market for drug-eluting stents (DES). The war has caused interruptions in the worldwide supply chain, resulting in higher DES prices. Furthermore, the war has created economic instability, which has reduced demand for DES. As a result, the global DES market is likely to expand at a slower rate than it did prior to the war.

The war has caused interruptions in the global supply chain, resulting in higher DES prices. This is due to the fact that DES are built from a range of components, some of which come from Russia or Ukraine. Palladium, for example, is a critical component in the production of DES, and Russia is a large producer of palladium. As a result of the battle, the price of palladium has risen, resulting in higher DES prices.

Because of the war's economic instability, demand for DES has fallen. This is because when there is economic uncertainty, people are less willing to spend money on elective operations such as coronary artery stenting. Thus, the global drug-eluting stent market is expected to expand at a slower rate than it did prior to the war. The market is still likely to develop, but at a slower rate than it would have been without the war.

Segment Analysis

The global drug eluting stents market is segmented based on coating, application, end user, and region.

The Coronary Artery Disease Segment is expected to hold a Dominant Position accounting for 74.1% of the Global Drug Eluting Stent Market over the Forecast Period

The coronary artery disease (CAD) is characterized by narrowing or blockage of the coronary arteries, which provide blood to the heart muscle. It is a prevalent cardiovascular disease that is a primary cause of morbidity and mortality worldwide. Several variables, including the high prevalence of coronary artery disease, and proven efficacy in CAD treatment, contribute to the coronary artery disease segment's dominance in the global drug eluting stent market.

Coronary artery disease (CAD) is a common disease that affects a sizable section of the world's population. The prevalence of CAD is further increased by the rising incidence of risk factors such as sedentary behavior, poor eating habits, smoking, and obesity. For instance, according to a 2023 report by the Centers for Disease Control and Prevention (CDC), about 375,476 people died from CAD in 2021 alone.

Moreover, CAD affects about 5% of persons aged 20 and over which shows how severely it affects a sizeable segment of the population. Alarmingly, in 2021, over 2 out of every 10 deaths from CAD occurred in those under the age of 65, emphasizing its effect on people who are relatively younger. Thus, owing to this reason the market for drug eluting stent will escalate at a higher CAGR over the forecast period.

Geographical Analysis

North America holds a Dominant Position in the Global Drug Eluting Stent Market.

North America is estimated to hold around 39.6% of the total market share throughout the forecast period, owing to the well-established healthcare infrastructure, favorable reimbursement policies, and presence of leading market players.

The recent collaborative efforts and agreements among companies are driving the market. For instance, in May 2023, CoSo Health and Medinol collaborated together to make EluNIR available in the United States. Medinol is renowned internationally for its experience developing ground-breaking implantable medical devices. Endovascular, a reputed distributor of peripheral and coronary devices, plays a vital role in ensuring the widespread availability of these goods.

Competitive Landscape

The major global players in the market include: Boston Scientific Corp., Abbott Laboratories, Medtronic Plc, Biotronik Inc., Johnson & Johnson, MicroPort Scientific Corporation, Cook Medical Inc., Stentys S.A., Biosensors International Group, and Terumo Corp., among others.

Why Purchase the Report?

To visualize the global drug eluting stents market segmentation based on the coating, application, end user and region, as well as understand key commercial assets and players.
Identify commercial opportunities by analyzing trends and co-development.
Excel data sheet with numerous data points of drug eluting stents market-level with all segments.
PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
Product mapping available as Excel consisting of key products of all the major players.

The global drug eluting stents market report would provide approximately 49 tables, 53 figures, and 195 Pages.

Target Audience 2023

Manufacturers/ Buyers
Industry Investors/Investment Bankers
Research Professionals
Emerging Companies

1. Methodology and Scope

1.1. Research Methodology
1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

3.1. Snippet by Coating
3.2. Snippet by Application
3.3. Snippet by End User
3.4. Snippet by Region

4. Dynamics

4.1. Impacting Factors
- 4.1.1. Drivers
  - 4.1.1.1. Growing Aging Population
  - 4.1.1.2. Adoption towards Minimal Invasive Procedures
- 4.1.2. Restraints
  - 4.1.2.1. High Cost associated with Drug Eluting Stent
- 4.1.3. Opportunity
- 4.1.4. Impact Analysis

5. Industry Analysis

5.1. Porter's 5 Forces Analysis
5.2. Supply Chain Analysis
5.3. Unmet Needs
5.4. Regulatory Analysis

6. COVID-19 Analysis

6.1. Analysis of COVID-19
- 6.1.1. Scenario Before COVID-19
- 6.1.2. Scenario During COVID-19
- 6.1.3. Scenario Post COVID-19
6.2. Pricing Dynamics Amid COVID-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During the Pandemic
6.5. Manufacturers' Strategic Initiatives
6.6. Conclusion

7. Russia-Ukraine War Analysis

8. By Coating

8.1. Introduction
- 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Coating
- 8.1.2. Market Attractiveness Index, By Coating
8.2. Polymer-based Coating Stents*
- 8.2.1. Introduction
- 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Polymer-free Coating Stents

9. By Application

9.1. Introduction
- 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 9.1.2. Market Attractiveness Index, By Application
9.2. Coronary Artery Diseases*
- 9.2.1. Introduction
- 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Peripheral Artery Disease

10. By End User

10.1. Introduction
- 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
- 10.1.2. Market Attractiveness Index, By End User
10.2. Hospitals*
- 10.2.1. Introduction
- 10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
10.3. Ambulatory Surgical Centers
10.4. Cardiac Centers

11. By Region

11.1. Introduction
- 11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
- 11.1.2. Market Attractiveness Index, By Region
11.2. North America
- 11.2.1. Introduction
- 11.2.2. Key Region-Specific Dynamics
- 11.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Coating
- 11.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 11.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User Type
- 11.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 11.2.6.1. The U.S.
  - 11.2.6.2. Canada
  - 11.2.6.3. Mexico
11.3. Europe
- 11.3.1. Introduction
- 11.3.2. Key Region-Specific Dynamics
- 11.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Coating
- 11.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 11.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
- 11.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 11.3.6.1. Germany
  - 11.3.6.2. The U.K.
  - 11.3.6.3. France
  - 11.3.6.4. Italy
  - 11.3.6.5. Spain
  - 11.3.6.6. Rest of Europe
11.4. South America
- 11.4.1. Introduction
- 11.4.2. Key Region-Specific Dynamics
- 11.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Coating
- 11.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 11.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
- 11.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 11.4.6.1. Brazil
  - 11.4.6.2. Argentina
  - 11.4.6.3. Rest of South America
11.5. Asia-Pacific
- 11.5.1. Introduction
- 11.5.2. Key Region-Specific Dynamics
- 11.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Coating
- 11.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 11.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
- 11.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 11.5.6.1. China
  - 11.5.6.2. India
  - 11.5.6.3. Japan
  - 11.5.6.4. Australia
  - 11.5.6.5. Rest of Asia-Pacific
11.6. Middle East and Africa
- 11.6.1. Introduction
- 11.6.2. Key Region-Specific Dynamics
- 11.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Coating
- 11.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 11.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User

12. Competitive Landscape

12.1. Competitive Scenario
12.2. Product Benchmarking
12.3. Company Share Analysis
12.4. Key Developments and Strategies

13. Company Profiles

13.1. Boston Scientific Corp.*
- 13.1.1. Company Overview
- 13.1.2. Product Portfolio and Description
- 13.1.3. Financial Overview
- 13.1.4. Key Developments
13.2. Abbott Laboratories
13.3. Medtronic Plc
13.4. Biotronik Inc.
13.5. Johnson & Johnson
13.6. MicroPort Scientific Corporation
13.7. Cook Medical Inc.
13.8. Stentys S.A.
13.9. Biosensors International Group
13.10. Terumo Corp.

LIST NOT EXHAUSTIVE